SAO PAULO (Reuters) -Brazilian pharmaceutical company EMS on Friday said that local pharmacies will start selling its injector pens aimed at treating diabetes and obesity from August 4.
The pens, made in Brazil, uses liraglutide as an active ingredient, like Saxenda, from Novo Nordisk, which has demonstrated consistent benefits in controlling blood glucose and weight, EMS said.
Saxenda is part of the same class of medication as Nordisk’s popular Ozempic.
A total of 100,000 Olire pens, for the treatment of obesity, and 50,000 Lirux pens, for the control of type 2 diabetes, will be available at select pharmacy chains in Brazil.
The launch of both medications comes as Brazilian companies, including EMS and rival Hypera Pharma, gear up to launch semaglutide medications next year, as Ozempic’s patent in the country is expected to expire in March.
(Reporting by Paula Arend Laier; Editing by David Holmes)
Comments